The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability

References

• Centers for Disease Control and PreventionTrends in drug- poisoning deaths involving opioid analgesics and heroin: United States, 1999–2012 Available from: http://www.cdc.gov/nchs/data/hestat/drug_poisoning/drug_poisoning.htmAccessed January 31, 2015
   Google Scholar
• Centers for Disease Control and PreventionPrescription drug overdose in the United States: fact sheet Available from: http://www.cdc.gov/homeandrecreationalsafety/overdose/facts.htmlAccessed January 31, 2015
   Google Scholar
• WebsterLRCochellaSDasguptaNAn analysis of the root causes for opioid-related overdose deaths in the United StatesPain Med201112Suppl 2S26S3521668754
   PubMed Web of Science ®Google Scholar
• MeierBPain Killer: The Extraordinary and True Story of OxyContinEmmaus, PA, USARodale Press2003
   Google Scholar
• Substance Abuse and Mental Health Services AdministrationResults from the 2008 National Survey on Drug Use and Health: National FindingsRockville, MD, USAOffice of Applied StudiesNSDUH Series H-36, HHS Publication No SMA 09-44342009
   Google Scholar
• Missouri Prescription Drug Monitoring Program NOW CoalitionCoalition News Release11242014 Available from: http://mopdmpnow.org/media/coalition-news-releases/Accessed February 3, 2015
   Google Scholar
• FlemingMLChandwaniHBarnerJCWeberSNOkoroTTPrescribers and pharmacists requests for prescription monitoring program (PMP) data: does PMP structure matter?J Pain Palliat Care Pharmacother20132713614223688495
   PubMedGoogle Scholar
• Indiana RegisterMedical licensing board of Indiana. Emergency rule. LSA document 13-495E Available from: http://www.in.gov/legislative/iac/20131030-IR-844130495ERA.xml.pdfAccessed February 25, 2015
   Google Scholar
• GourlayDLHeitHAAlmahreziAUniversal precautions in pain medicine: a rational approach to the treatment of chronic painPain Med2005610711215773874
   PubMed Web of Science ®Google Scholar
• DarnallDBSchatmanMEUrine drug screening: opioid risks preclude complete patient autonomyPain Med2014152001200225376661
   PubMed Web of Science ®Google Scholar
• GoldbergDSRichBAPharmacovigilance and the plight of chronic pain patients: in pursuit of a realistic and responsible ethic of careIndiana Health Law Rev20141183122
   Google Scholar
• ArnoldRMHanPKSeltzerDOpioid contracts in chronic nonmalignant pain management: objectives and uncertaintiesAm J Med200611929229616564767
   PubMed Web of Science ®Google Scholar
• StarrelsJLBeckerWCAlfordDPKapoorAWilliamsARTurnerBJSystematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic painAnn Intern Med201015271272020513829
   PubMed Web of Science ®Google Scholar
• SchatmanMEDarnallBD“Just saying no” to mandatory pain CME: how important is physician autonomy?Pain Med20131418211825
   Web of Science ®Google Scholar
• ThomasDFrascellaJHallTReflections on the role of opioids in the treatment of chronic pain: a shared solution for prescription opioid abuse and painJ Intern Med12302014 Epub ahead of print
   Web of Science ®Google Scholar
• CainJMandatory CME on opioid prescribing fails to address true causes of prescription drug abusePain Med20131418211822
   Web of Science ®Google Scholar
• HaegerichTMPaulozziLJMannsBJJonesCMWhat we know, and don’t know, about the impact of state policy and systems-level interventions on prescription drug overdoseDrug Alcohol Depend2014145344725454406
   PubMed Web of Science ®Google Scholar
• CheungCWQiuQChoiSWMooreBGouckeRIrwinMChronic opioid therapy for chronic non-cancer pain: a review and comparison of treatment guidelinesPain Physician20141740141425247898
   PubMed Web of Science ®Google Scholar
• DunnKMSaundersKWRutterCMOpioid prescriptions for chronic pain and overdose: a cohort studyAnn Intern Med2010152859220083827
   PubMed Web of Science ®Google Scholar
• FranklinGMMaiJTurnerJSullivanMWickizerTFulton-KehoeDBending the prescription opioid dosing and mortality curves: impact of the Washington State opioid dosing guidelineAm J Ind Med20125532533122213274
   PubMed Web of Science ®Google Scholar
• GargRKFulton-KehoeDTurnerJAChanges in opioid prescribing for Washington workers’ compensation claimants after implementation of an opioid dosing guideline for chronic noncancer pain: 2004 to 2010J Pain2013141620162824290443
   PubMed Web of Science ®Google Scholar
• AnsonPDeath rate from painkiller overdoses drops in Washington StateNational Pain Report1282013 Available from: http://nationalpainreport.com/death-rate-from-painkiller-overdoses-drops-in-washington-state-8818418.htmlAccessed February 5, 2015
   Google Scholar
• FranklinGMFulton-KehoeDTurnerJASullivanMDWickizerTMChanges in opioid prescribing for chronic pain in Washington StateJ Am Board Fam Med20132639440023833154
   PubMed Web of Science ®Google Scholar
• BaumCHsuJPNelsonRCThe impact of the addition of naloxone on the use and abuse of pentazocinePublic Health Rep19871024264293112855
   PubMed Web of Science ®Google Scholar
• CiceroTJInciardiJAMuñozATrends in abuse of OxyContin and other opioid analgesics in the United States: 2002–2004J Pain2005666267216202959
   PubMed Web of Science ®Google Scholar
• Moorman-LiRMotyckaCAIngeLDCongdonJMHobsonSPokropskiBA review of abuse-deterrent opioids for chronic nonmalignant painP T20123741241822876107
   PubMedGoogle Scholar
• SevertsonSGBartelsonBBDavisJMReduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010J Pain2013141122113023816949
   PubMed Web of Science ®Google Scholar
• ButlerSFCassidyTAChilcoatHAbuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatmentJ Pain20131435135823127293
   PubMed Web of Science ®Google Scholar
• CoplanPMKaleHSandstromLLandauCChilcoatHDChanges in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristicsPharmacoepidemiol Drug Saf2013221274128224123484
   PubMed Web of Science ®Google Scholar
• SesslerNEDowningJMKaleHChilcoatHDBaumgartnerTFCoplanPMReductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulationPharmacoepidemiol Drug Saf2014231238124624916486
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services/Food and Drug AdministrationFDA approves abuse-deterrent labeling for reformulated OxyContin4162013 Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm348252.htmAccessed February 6, 2015
   Google Scholar
• VosburgSKJonesJDManubayJMAshworthJBBenedekIHComerSDAssessment of a formulation designed to be crush-resistant in prescription opioid abusersDrug Alcohol Depend201212620621522721679
   PubMed Web of Science ®Google Scholar
• VosburgSKJonesJDManubayJMAshworthJBShapiroDYComerSDA comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusersAddiction20131081095110623316699
   PubMed Web of Science ®Google Scholar
• LavonasEJSevertsonSGMartinezEMAbuse and diversion of buprenorphine sublingual tablets and filmJ Subst Abuse Treat201447273424680219
   PubMed Web of Science ®Google Scholar
• SchatmanMEDarnallBDA practical and ethical solution to the opioid scheduling conundrumJ Pain Res201471324353439
   PubMed Web of Science ®Google Scholar
• SchatmanMEThe demise of multidisciplinary pain management clinics?Pract Pain Manag200663041
   Google Scholar
• SchatmanMEThe demise of the multidisciplinary chronic pain management clinic: bioethical perspectives on providing optimal treatment when ethical principles collideSchatmanMEEthical Issues in Chronic Pain ManagementNew York, NY, USAInforma Healthcare2007
   Google Scholar
• SchatmanMEGiordanoJSchatmanMEA crisis in pain care: an ethical analysis. Part 1. Facts, issues, and problemsPain Physician20081148349018690277
   PubMed Web of Science ®Google Scholar
• GiordanoJSchatmanMEA crisis in chronic pain care: an ethical analysis. Part 3: Toward an integrative, multi-disciplinary pain medicine built around the needs of the patientPain Physician200811771784
   Web of Science ®Google Scholar
• RobinsonJPLeoRWallachJMcGoughESchatmanMERehabilitative treatment for chronic painStannardCKalsoEBallantyneJCEvidence-Based Chronic Pain ManagementOxford, UK, USABlackwell Publishing2010407423
   Google Scholar
• SchatmanMEInterdisciplinary chronic pain management: perspectives on history, current status, and future viabilityBallantyneJCRathmellJPFishmanSMBonica’s Management of Pain4th editionPhiladelphia, PA, USALippincott, Williams & Wilkins201015231532
   Google Scholar
• SchatmanMESullivanJWhither suffering? The potential impact of tort reform on the emotional and existential healing of traumatically injured chronic pain patientsPsychol Inj Law20103182202
   Google Scholar
• SchatmanMEThe role of the health insurance industry in perpetuating suboptimal pain management: ethical implicationsPain Med20111241542621332933
   PubMed Web of Science ®Google Scholar
• KitaharaMKojimaKKOhmuraAEfficacy of interdisciplinary treatment for chronic nonmalignant pain patients in JapanClin J Pain20062264765516926581
   PubMed Web of Science ®Google Scholar
• TurkDCSwansonKEfficacy and cost-effectiveness treatment for chronic pain: an analysis and evidence-based synthesisSchatmanMECampbellAChronic Pain Management: Guidelines for Multidisciplinary Program DevelopmentNew York, NY, USAInforma Healthcare20071538
   Google Scholar
• StanosSFocused review of interdisciplinary pain rehabilitation programs for chronic pain managementCurr Pain Headache Rep20121614715222427179
   PubMed Web of Science ®Google Scholar
• GatchelRJMcGearyDDMcGearyCALippeBInterdisciplinary chronic pain management: past, present, and futureAm Psychol20146911913024547798
   PubMed Web of Science ®Google Scholar
• TurkDCClinical effectiveness and cost-effectiveness of treatments for patients with chronic painClin J Pain20021835536512441829
   PubMed Web of Science ®Google Scholar
• GatchelRJOkifujiAEvidence-based scientific data documenting the treatment and cost-effectiveness of comprehensive pain programs for chronic nonmalignant painJ Pain2006777979317074616
   PubMed Web of Science ®Google Scholar
• AnooshianJStreltzerJGoebertDEffectiveness of a psychiatric pain clinicPsychosomatics19994022623210341535
   PubMed Web of Science ®Google Scholar
• SchatmanMEInterdisciplinary chronic pain management: international perspectivesPain: Clinical Updates201220715
   Google Scholar
• PoitrasGOxyContin, prescription opioid abuse and economic medicalizationMedicolegal Bioethics201223143
   Google Scholar
• RobbinsHGatchelRJNoeCA prospective one-year outcome study of interdisciplinary chronic pain management: compromising its efficacy by managed care policiesAnesth Analg20039715616212818959
   PubMed Web of Science ®Google Scholar
• OkifujiAInterdisciplinary pain management with pain patients: evidence for its effectivenessSem Pain Med20031110119
   Google Scholar
• BosyDEtlinDCoreyDLeeJWAn interdisciplinary pain rehabilitation programme: description and evaluation of outcomesPhysiother Can20106231632621886371
   PubMed Web of Science ®Google Scholar
• MurphyJLClarkMEBanouEOpioid cessation and multidimensional outcomes after interdisciplinary chronic pain treatmentClin J Pain20132910911722751033
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention: Vital signs: risk for overdose from methadone used for pain relief – United States, 1999–2010MMWR Morb Mortal Wkly Rep20126149349722763888
   PubMedGoogle Scholar
• ChouRCrucianiRAFiellinDAMethadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm SocietyJ Pain20141532133724685458
   PubMed Web of Science ®Google Scholar
• American Academy of Pain MedicineThe evidence against methadone as a “preferred” analgesic: a position statement from the American Academy of Pain Medicine2014 Available from: http://www.painmed.org/files/the-evidence-against-methadone-as-a-preferred-analgesic.pdfAccessed February 19, 2015
   Google Scholar
• BrooksMJMitigating the safety risks of drugs with a focus on opioids: are risk evaluation and mitigation strategies the answer?Mayo Clin Proc2014891673168425441401
   PubMed Web of Science ®Google Scholar
• PassikSDIssues in long-term opioid therapy: unmet needs, risks, and solutionsMayo Clin Proc20098459360119567713
   PubMed Web of Science ®Google Scholar
• SchneiderJPMatthewsMJamisonRNAbuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?CNS Drugs20102480581020839893
   PubMed Web of Science ®Google Scholar
• RomachMKSchoedelKASellersEMUpdate on tamper-resistant drug formulationsDrug Alcohol Depend2013130132323415386
   PubMed Web of Science ®Google Scholar
• BrushwoodDBRichBAColemanJJBolenJWongWLegal liability perspectives on abuse-deterrent opioids in the treatment of chronic painJ Pain Palliat Care Pharmacother20102433334821133741
   PubMedGoogle Scholar
• ArgoffCEStanosSPWiemanMSValidity testing of patient objections to acceptance of tamper-resistant opioid formulationsJ Pain Res2013636737323696714
   PubMed Web of Science ®Google Scholar
• CiceroTJKurtzSPSurrattHLMultiple determinants of specific modes of prescription opioid diversionJ Drug Issues20114128330422287798
   PubMed Web of Science ®Google Scholar
• Ben-JosephRChenCCDeAPWadeRLShahDConsequences of patient access restrictions to branded oxycodone hydrochloride extended-release tablets on healthcare utilization and costs in US health plansJ Med Econ20141770871824888403
   PubMedGoogle Scholar
• KirsonNYSheiAWhiteAGSocietal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United StatesPain Med2014151450145425041231
   PubMed Web of Science ®Google Scholar
• ButlerSFFernandezKCChangAMeasuring attractiveness for abuse of prescription opioidsPain Med201011678020002325
   PubMed Web of Science ®Google Scholar
• CiceroTJEllisMSSurrattHLEffect of abuse-deterrent formulation of OxyContinN Engl J Med201236718718922784140
   PubMed Web of Science ®Google Scholar
• HallAJLoganJEToblinRLPatterns of abuse among unintentional pharmaceutical overdose fatalitiesJAMA20083002613262019066381
   PubMed Web of Science ®Google Scholar
• KatzNPBirnbaumHBrennanMJPrescription opioid abuse: challenges and opportunities for payersAm J Manag Care20131929530223725361
   PubMed Web of Science ®Google Scholar
• BrownERLavarredaSARiceTKincheloeJRGatchellMSThe state of health insurance in California: findings from the 2003 California Health Interview Survey (August 2005) Available from: http://ucla-dev-web01.reliam.com/publications/Documents/PDF/The%20State%20of%20Health%20Insurance%20in%20California%20Findings%20from%20the%202003%20California%20Health%20Interview%20Survey.pdfAccessed February 13, 2015
   Google Scholar
• VietriJJoshiABBarsdorfAIMerdekianJPrescription opioid abuse and tampering in the United States: results of a self-report surveyPain Med2014152064207424931057
   PubMed Web of Science ®Google Scholar
• HaasMDe Abreu LourencoRPharmacological management of chronic lower back pain: a review of cost effectivenessPharmacoeconomics1222015 Epub ahead of print
   Web of Science ®Google Scholar
• NayakRKPearsonSDThe ethics of ‘fail first”: guidelines and practical scenarios for step therapy coverage policiesHealth Aff (Millwood)2014331779178525288422
   PubMed Web of Science ®Google Scholar
• IrwinJAHopkinsTConfordPSign up to support legislation in the New York state legislature that seeks to regulate “first fail” or “step therapy” drug policies imposed by health insurance companies Available from: http://www.epilepsyuny.org/Documents/Step%20Therapy%20Advocacy%20Pkg.%2009%2009%2013.pdfAccessed February 20, 2015
   Google Scholar